Given that osteolytic lesions can occur in other hematological malignancies (i.e., multiple myeloma), ruling out concurrent disease is necessary (i.e., serum protein electrophoresis, parathyroid hormone) [10, 14, 17]. This evidence concerns the gene PTH and hematologic disorder.